SAM
DFTX

Smartleaf Asset Management’s Definium Therapeutics DFTX Stock Holding History

Smartleaf Asset Management’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10K Hold
215
– – ﹤0.01% 2364
2026
Q1 		$3.76K Buy
+215
New +$3.65K ﹤0.01% 2778

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Smartleaf Asset Management's DFTX Position: Q2 2026 in Review

Smartleaf Asset Management held its Definium Therapeutics (DFTX) position steady in Q2 2026 at 215 shares worth $10K. The position accounts for ﹤0.01% of the portfolio, ranked #2364.

Smartleaf Asset Management first reported a position in DFTX in Q1 2026 and has held it in 2 quarters since. 361 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • Smartleaf Asset Management held 215 shares of Definium Therapeutics worth $10K as of Q2 2026.
  • Smartleaf Asset Management left its Definium Therapeutics share count unchanged in Q2 2026.
  • Definium Therapeutics made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q2 2026, its #2364 holding.
  • Smartleaf Asset Management first reported a position in Definium Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 361 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Smartleaf Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.